All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
The STRATUS (MM-010) phase-3b clinical trial, to further explore the efficacy of pomalidomide plus low-dose dexamethasone in patients with relapsed and/or refractory Multiple myeloma (RRMM), was led by Meletios Dimopoulos and Philippe Moreau, and the results published in Blood in July 2016. In the largest cohort to date, 682 patients (median age of 66 years and a median time from initial diagnosis of 5.3 years) with RRMM, were enrolled between November 2012 and December 2014.
Using the largest cohort to date of heavily pre-treated RRMM patients, the clinical benefit of pomalidomide plus low-dose dexamethasone was further demonstrated, as well as good overall tolerability. This corroborates the data from the previous MM-002 and MM-003 pivotal trials, and indicated little sub-group differences according to age or prior treatment regimen. This therefore provides viable treatment option for RRMM patients that have exhausted other avenues.
Subscribe to get the best content related to multiple myeloma delivered to your inbox